Eylea drives increase in net income for Regeneron

Regeneron Pharmaceuticals reported a net income of $750.3 million in 2012, compared with a net loss of $221.8 million in 2011, according to a company press release.Revenues increased from $445.8 million in 2011 to $1.4 billion in 2012. Eylea (aflibercept) accounted for $838 million in U.S. net sales in 2012, leading to Regeneron’s first full year of profitability, according to the release.

Full Story →